Cosyntropin vs Ziconotide
Head-to-head comparison of Cosyntropin (Cosyntropin (ACTH 1-24)) and Ziconotide (ω-Conotoxin MVIIA (ziconotide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cosyntropin | Ziconotide |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Cosyntropin (ACTH 1-24) | ω-Conotoxin MVIIA (ziconotide) |
| Molecular Weight | 2933.3 Da | 2639.1 Da |
| Half-Life | ~10 min | approximately 4.5 hours |
| Amino Acids | 24 | 25 |
| Typical Dose | 0.25 mg IV/IM diagnostic dose|off-label headache protocols vary | 0.5-19.2 mcg/day |
| Route | IV|IM | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 61 | 500 |
| Research Status | Clinical research | Approved |
Cosyntropin Benefits
- ✓refractory migraine
- ✓anti-inflammatory signaling
- ✓headache rescue research
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
Cosyntropin Dosing
0.25 mg IV/IM|1 mg IV/IM
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
Cosyntropin Side Effects
- ⚠flushing
- ⚠nausea
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Research Overview
Cosyntropin
Cosyntropin is not a standard pain drug, but it appears in headache literature because ACTH analogs can help some patients with difficult migraine attacks. The analgesic rationale is partly tied to steroidogenic and anti-inflammatory effects.
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.